Ironwood Pharmaceuticals Inc (IRWD)
- Sector
- Biotechnology
- Last price
- $3.60
- As of
Kresmion compiles this page from IRWD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
IRONWOOD PHARMACEUTICALS INC (IRWD): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full IRWD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IRWD on one page. Preview it with sample data, then open it live with a free account.
Preview the IRWD dossierActive signals for IRWD
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +618% to IRWD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3567% to IRWD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +455% to IRWD (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +156% to IRWD (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 14.6%, EPS $0.31 vs $0.3631 estimate
FREE, NO ACCOUNT
Every signal on IRWD, as it fires
You are seeing 5 of 12 signals recorded on IRWD since 2026-05-30.
The five above landed across 2 days. The other 7 were recorded on 3 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IRWD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 46333X108 · 2026Q2 | $33.7M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 46333X108 · 2026Q2 | $19.2M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 46333X108 · 2026Q2 | $2.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 46333X108 · 2026Q2 | $517K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IRWD
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IRWD against its peers
IRWD's operating margin of 33.3% ranks in the 85th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IRWD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 296M USD | 42.7M USD | 78 | 15 |
| Gross margin | n/a | 87.1% | n/a | 5 |
| Operating margin | 33.3% | -139.3% | 85 | 16 |
| Net margin | 8.1% | -145.4% | 74 | 16 |
| Return on equity | n/a | -52.5% | n/a | 22 |
| P / E | 24.0x | n/a | n/a | 3 |
| 1 year | 143.2% | -3.0% | 83 | 20 |
Peers (23): CLYM, STTK, AURA, SGMT, DBVT, WVE, NVCT, OLMA, PRME, PHAT, CRMD, ZVRA, VALN, PHAR, CTMX, VSTM, SLN, MDXG, XOMA, CADL, FDMT, CBIO, SLDB. Left out: BLSM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IRWD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IRWD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IRWD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.